A

Aeglea BioTherapeutics

79 employees

Aeglea BioTherapeutics is a clinical-stage biotechnology company that develops enzyme therapies for rare metabolic diseases.

Basic info

Industry

biotechnology research

Sectors

Biotechnology
biotechnology
Health Care
rare disease
human enzymes
Therapeutics
engineering enzymes
biotech

Date founded

2013

Funding rounds raised

Total raised

$44M

from 10 investors over 10 rounds

A

Aeglea BioTherapeutics raised $44M on March 23, 2015

Investors: Jennison Associates LLC, UT Horizon Fund, Lilly Ventures, OrbiMed Advisors, RA Capital Management, L.P., New Ground Ventures and Venrock

A

Aeglea BioTherapeutics raised $12M on February 6, 2014

Investors: Lilly Ventures, KBI Biopharma and UT Horizon Fund

FAQ